


Supplementary Figure 1



Supplementary Figure S1. The median PFS in phase I trials was not inferior to the median PFS on the last FDA-approved therapy for the subset of patients with HNSCC.

SUPPLEMENTARY TABLE 1. Summary of last treatment prior to inclusion in phase I trials. All patients received treatments using FDA-approved drugs as the backbone of therapy.

TREATMENT GROUP	DRUGS	Number
PLATINUM-BASED	Carboplatin-Taxol	8
	Cisplatin-Taxol	1
	Cisplatin-Vinorelbine	1
	Carboplatin -Docetaxel	1
	Carboplatin -Gemcitabine	1
	Carboplatin -Taxol-TMP470	1
	Carboplatin -Docetaxel-Cetuximab	1
	Carboplatin -Docetaxel-Tarceva	1
	Cisplatin-5FU-Docetaxel	1
	Carboplatin -Taxol-Cetuximab	2
	Cisplatin -Cetuximab	1
	Cisplatin -Taxol-5FU-Cetuximab	1
	TOTAL PLATINUM	20 (34%)
	Anti-EGFR	Cetuximab
Gefitinib		7
Erlotinib		6
Cetuximab-Ifosfamide		2
Cetuximab-IMCA12		1
Cetuximab-Avastin		1
TOTAL ANTI-EGFR		25 (42%)

TREATMENT GROUP	DRUGS	Number
Taxanes	Docetaxel	2
	Docetaxel-Lonafarnib	1
	Docetaxel-Cetuximab	1
	TOTAL TAXANES	4 (7%)
Antifolates	Alimta	8
	TOTAL ANTIFOLATES	8 (14%)
Other cytotoxics	Gemcitabine	1
	Adriamycin-Ciclofosfamide	1
	TOTAL OTHER CYTOTOXICS	2 (3%)
	TOTAL	59 (100%)

TMP470 (antiangiogenic), 5FU (5-Fluoruracil), IMCA12 (monoclonal antibody anti-IGFR)